Investigational medicinal products were procured from Micro Labs Ltd., Bangalore, India, which included the test product, losartan potassium tablets 100 mg of Micro Labs Ltd., India and the reference product, Cozaar® 100 mg of losartan potassium tablets of Merck and Co., INC., USA.
Cozaar
Manufactured by Merck Group
Sourced in United States
Cozaar is a laboratory equipment product manufactured by the Merck Group. It is designed for use in scientific research and analysis. The core function of Cozaar is to provide a reliable and precise tool for researchers, without any additional interpretation or extrapolation on its intended use.
Automatically generated - may contain errors
Lab products found in correlation
4 protocols using cozaar
1
Comparative Evaluation of Losartan Formulations
2
Losartan Therapy in DyW Muscular Dystrophy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Heterozygous B6.129 Lama2dy-W/+ (DyW) mice carrying a mutation in the LAMA2 gene were kindly provided by Dr. Eva Engvall (Burnham Institute, La Jolla, CA, USA) and housed in the Laboratory Animal Care Facility at the Charles River Campus of Boston University on a 12:12 hour light-dark cycle. All animal procedures were approved by IACUC at Boston University (permit number 13–055) and conducted to minimize animal suffering at all times. Losartan was provided in the drinking water ad libitum (600mg/L, Cozaar by Merck pharmaceuticals with 25 g/L of sucrose to increase palatability) beginning at week two until collection at week seven [11 (link)]. Typically, animal water consumption is in the range of 1.5ml/10g/day [12 (link)]. At seven weeks of age, following 5 weeks of treatment, animals were shipped to University of Florida for skeletal muscle imaging in the Advanced Magnetic Resonance and Spectroscopy (AMRIS) facility. All animals were imaged and euthanized with overdose of Isoflurane within 24 hours of arrival. Hind limb muscles were extracted for histological and biochemical analyses and shipped back to Boston University for further analysis.
3
Angiotensin II Receptor Antagonist in Fear Extinction
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Seventy healthy males underwent a validated Pavlovian threat acquisition and extinction procedure with simultaneous fMRI and SCR acquisition. To reduce variance related to hormonal and menstrual-cycle-associated variation in extinction [23] [24] [25] only male participants were included in the present proof-of-concept experiment [for similar approach see ref. The experiment consisted of three sequential stages: (1) acquisition, (2) treatment administration and, (3) extinction. 20-min after acquisition, participants were administered either a single 50mg (p.o.) dose of the selective, competitive angiotensin II type 1 receptor antagonist losartan (LT, Cozaar; Merck, USA) or placebo (PLC), packed in identical capsules. Consistent with the pharmacodynamic profile of LT [27] extinction was observed 90min post-treatment. Although previous studies reported no effects of single-dose LT on cardiovascular activity or mood [18, 27, 28] , these indices were monitored to primarily control for unspecific effects of treatment and not focused on behavior per se. The experimental time-line is provided in Fig. 1a (for the pharmacodynamic profile and assessment of confounders see Supplementary
4
Losartan Ameliorates Diabetic Liver Damage
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
DM was induced in 28 rats by intraperitoneal injection of STZ (Sigma-Aldrich, St. Louis, MO, USA) (50 mg/kg in 0.1 M citrate buffer, pH 4.5). No drug was administered to the other 7 rats that all had blood glucose levels of <120 mg/dL (control group, n = 7). DM was verified after 24 h by evaluating the blood glucose levels. Rats with blood glucose levels of >250 mg/dL were included in the study as the diabetic rat group (n = 28) [19]. The 28 diabetic rats were then randomly separated into 4 groups. For a period of 4 weeks, the DM group (n = 7) was given no medication. The DM + low-dose losartan group (n = 7) was administered 5 mg/kg/day oral losartan (Cozaar, 50 mg; Merck Sharp & Dohme, Kenilworth, NJ, USA) for a 4-week period. The DM + mid-dose losartan group (n = 7) was administered 20 mg/kg/day oral losartan for a 4-week period. The DM + high-dose losartan group (n = 7) was administered 80 mg/kg/day oral losartan for a 4-week period.
At the end of the study, blood samples of 1 mL were taken into heparinized tubes for biochemical analysis from the rats, which were sedated under anesthesia. After bloodletting, liver tissues of euthanized rats were rapidly dissected for histopathological and immunohistochemical examinations.
At the end of the study, blood samples of 1 mL were taken into heparinized tubes for biochemical analysis from the rats, which were sedated under anesthesia. After bloodletting, liver tissues of euthanized rats were rapidly dissected for histopathological and immunohistochemical examinations.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!